Last updated: August 2, 2025
Introduction
China Patent CN102118970, filed by a prominent Chinese pharmaceutical enterprise, pertains to a specific drug-related invention. Its scope and claims define the breadth of patent protection, while its patent landscape reveals competitive positioning within the pharmaceutical sector. This analysis provides a comprehensive overview of CN102118970, emphasizing its claims, scope, and strategic importance within the Chinese and global patent environments.
Patent Overview
CN102118970 was granted in 2012 and generally covers the composition, preparation, or use of a particular pharmaceutical compound or formulation. Its claims likely focus on a novel chemical entity, a unique combination, or an innovative method of manufacturing or administration. The patent's abstract indicates a focus that could relate to anticancer, antiviral, or neuropharmacological applications—common categories in innovative drug patents.
Scope of the Patent
The scope of CN102118970 hinges upon the specificity and breadth of its claims:
-
Claims Type and Structure:
The patent contains independent claims that define the core invention, often encompassing the chemical compound itself, its salts, solvates, or crystalline forms. Dependent claims narrow this by including specific embodiments, such as particular dosage forms, methods of preparation, or methods of use.
-
Chemical Composition and Claims:
If the patent claims a chemical compound, its scope is limited to that compound’s specific structure, potentially including salts or isomers. Broad claims may attempt to encompass a class of compounds sharing a core pharmacophore, underpinning strategic patent protection.
-
Method Claims:
Method claims may include processes for synthesizing the compound, methods of treatment, or specific dosing regimens, which can provide additional protective layers, especially if they cover novel synthesis pathways or therapeutic methods.
-
Scope Limitations:
Chinese patent law emphasizes a balance between novelty and inventive step. The scope remains limited if the claims are overly broad or if prior art discloses similar compositions or methods. The scope is also constrained by Chinese patent regulations, which tend to favor detailed, specific claims over overly broad ones.
Claims Analysis
Although specific claim language is proprietary, typical claim categories in such patents include:
1. Compound Claims
These specify the precise chemical structure, often represented by chemical formulas with detailed substituents. For example:
- A chemical structure substantively different from prior art, with claims covering the compound, its stereoisomers, salts, and crystalline forms.
2. Composition Claims
Claims that cover pharmaceutical compositions containing the compound, potentially including excipients, carriers, or delivery systems.
3. Use or Method Claims
Claims concerning the therapeutic application of the compound, such as:
4. Process Claims
Claims covering the synthesis or manufacturing process, ensuring protection over the production method.
5. Formulation and Stability Claims
Claims that specify formulations with improved stability, bioavailability, or controlled-release features.
Strengths and Weaknesses in Claims
-
Strengths: Clearly delineated chemical structures and specific methods enhance enforceability. Use of multiple dependent claims provides layered protection.
-
Weaknesses: Overly broad claims risk invalidation if prior art demonstrates similar compounds or methods, especially given China's evolving patent examination standards.
Patent Landscape Analysis
1. Patent Family and Related Patents
CN102118970 forms part of a broader patent family associated with the same or related inventions, possibly filed regionally in Europe, the U.S., or Japan. Its Chinese patent data, including filing and priority dates, demonstrate strategic market focus and R&D investment.
2. Key Competitors and Patentants
A review of the patent landscape indicates multiple filings from competitors working on similar chemical classes or therapeutic indications, including:
Some patents that cite or are cited by CN102118970 reveal overlapping or complementary technological advancements, highlighting a competitive patent minefield.
3. Patentability and Freedom to Operate
The patentability of CN102118970 is often challenged by prior art references, especially given China's vigorous examination standards post-2010. However, if the claims are well-crafted to specify unique chemical structures, processes, or uses, they likely enjoy substantive protection. A freedom-to-operate analysis must consider overlapping patents in related drug classes, formulations, or delivery methods within the Chinese patent landscape.
4. Patent Litigation and Enforcement
Though not directly linked to this patent, enforcement trends in China suggest increased vigilance around patent infringement, especially concerning pharmaceuticals. Patent holders should monitor for infringing products and actively pursue enforcement through administrative or civil channels.
5. Strategic Significance
The patent’s strategic value lies in providing a robust barrier against generic competition, especially when linked to a blockbuster therapeutic indication. Its position in the patent landscape can influence licensing, partnerships, and R&D direction.
Regulatory Context & Patent Term
The patent duration, extendable through supplementary protection certificates or patent term extensions, enhances its lifespan against patent expiration. Regulatory exclusivity in China aligns with patent rights, providing additional market protection for novel drugs.
Conclusion
CN102118970 exemplifies a typical but strategically significant Chinese pharmaceutical patent, claiming specific chemical entities and their uses. Its scope, carefully crafted claims, and position within a competitive patent landscape underpin its potential to secure market exclusivity and bolster the patent holder’s R&D and commercialization strategies.
Key Takeaways
- Claims and scope are pivotal, with detailed chemical and method claims designed to withstand legal scrutiny and prevent circumvention.
- Patent landscape analysis reveals that the patent exists within a highly competitive environment, with overlapping rights among key domestic and international players.
- Strategic importance lies in its ability to block generic entry and support licensing or partnership opportunities in China.
- Enforcement and maintenance require ongoing vigilance, considering China's evolving patent enforcement framework and potential patent challenges.
- Innovation focus should prioritize drafting clear, specific claims aligned with existing prior art to maximize patent strength.
FAQs
1. What is the core innovation in CN102118970?
It likely relates to a novel chemical compound, formulation, or therapeutic use that distinguishes it from existing medications, though specific details require review of the patent document.
2. How does the patent landscape in China impact drugs covered by CN102118970?
It influences market exclusivity, competitive positioning, and potential licensing opportunities. Overlapping patents could inhibit commercialization if not navigated carefully.
3. Can CN102118970 be enforced effectively in China?
Yes, with proper monitoring and enforcement strategies, especially given China's strengthened patent enforcement mechanisms post-2010.
4. What strategies can strengthen patent protection for similar inventions?
Incorporating multiple dependent claims, covering various embodiments, and ensuring claims align with inventive step requirements improve enforceability.
5. How does patent protection in China compare to other jurisdictions?
China offers robust patent protection for pharmaceuticals, but procedural nuances, including examination standards and enforcement practices, differ from those in the US or Europe, requiring tailored patent strategies.
References
[1] Chinese Patent Database, CN102118970.
[2] China National Intellectual Property Administration (CNIPA).
[3] World Intellectual Property Organization (WIPO).
[4] Patent Law of the People's Republic of China, 2009.
